Genovis AB signs a strategic cooperation agreement with Alphalyse A/S

17 March 2016

The cooperation agreement provides Genovis with access to Alphalyse’s expertise in mass spectrometry. In return, Alphalyse will have the opportunity to offer its customers analyses based on Genovis’ unique enzymes for antibodies and other pharmaceutical proteins.

March 17, 2016 – Much of Genovis’ customer base works with mass spectrometry in the analysis of biologics. Genovis and Alphalyse intend to actively market new methods based on Genovis’ products, which directly focus on this customer group. This strategy will strengthen Genovis, which will be able to expand its customer base and thus increase sales.

“Alphalyse has world-leading expertise in mass spectrometric analysis of proteins. So their knowledge of sample processing and the limitations of current enzymes enable us to use existing and upcoming products in applications where they will have maximum value. We are very pleased to have the opportunity to market and develop methods of mass spectrometric analysis together with Alphalyse. Therefore, I am convinced that this will be a long-term and mutually rewarding collaboration,” says Fredrik Olsson, CEO of Genovis.

“Genovis has unique enzymes and products that allow for better and faster analysis of protein-based drugs when using mass spectrometry. The collaboration thus provides Alphalyse with a major advantage in our work. This includes helping pharmaceutical companies that develop products such as monoclonal antibodies and antibody-drug conjugates for cancer treatment,” says Ejvind Mørtz, COO of Alphalyse.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB
T: +46 (0)46-12 12 33


Alphalyse is a contract research company (CRO). They possess cutting-edge expertise in mass spectrometry-based protein analysis for research, production and also clinical development of native and recombinant

Through its standard protein analysis services and customized analytical services, e.g. antibody sequencing, the company offers a range of unique high-quality protein analyses to identify and characterize
biopharmaceutical proteins. Examples also include as monoclonal antibodies and vaccines.

The services are used by the biotech industry, pharmaceutical companies and also academic research groups worldwide. Alphalyse has offices in Odense, Denmark and Palo Alto, California, USA.


Genovis markets its products under the name “Smart Enzymes”. Smart Enzymes process antibodies and thus split them into smaller fragments. To date, the products have been marketed primarily for characterization of biologics.

Customers use small quantities of the products in a large number of samples to divide the drug candidate into smaller fragments, which are then analyzed. All of the products are also highly effective in production of large quantities of antibody fragments, which are required in several different studies in preclinical drug discovery.

Genovis shares are listed on NASDAQ First North Stockholm and Consensus is the Company’s Certified Advisor, T: +46(0) 31 745 50 00